Breast Cancer

Atezolizumab (Tecentriq) plus chemotherapy is approved under the FDA’s Accelerated Approval Program, which allows conditional approval of a medicine that fills an unmet medical need for a serious or life-threatening disease or condition.

Patient-driven recommendations to reduce breast cancer-related economic burden could be key to shaping policies and interventions.

Top news of the week from Specialty Pharmacy Times.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Top news of the day from across the health care landscape.

The new class of smart drugs has the ability to bring the toxic payload directly to the cancer cells.

This study demonstrates the significance and efficacy of breast cancer screenings for prevention and early intervention.

Translational study of breast cancer therapy sought to ‘take research from bench to bedside.’

Ado-trastuzumab emtansine (Kadcyla) is currently approved for the treatment of patients with HER-2 positive metastatic breast cancer who previously received trastuzumab and a taxane.

Researchers have identified a link between CXCR4 expression, fibrosis, and immunosuppression in patients with metastatic breast cancer.

Top news of the day across the health care landscape.

Researchers aimed to better understand the different ways that breast cancer avoids immune system detection.

Study examines whether markers of biological aging due to cancer treatment are related to cognitive function in survivors of breast cancer.

Hot flashes are a huge problem across the general population, but even more so in breast cancer survivors.

The FDA has accepted Genentech’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in people whose disease expresses the PD-L1 protein, as determined by PD-L1 biomarker testing.

Top news of the day from across the health care landscape

Former New York Giants running back Tiki Barber discusses his mother's fight against breast cancer and his advocacy for cancer awareness.

Prescriptions for hormonal therapy medications increased in states that expanded Medicaid, according to a recent analysis.

Top news of the day from across the health care landscape.

Study highlights mechanism of endocrine resistance in estrogen receptor-positive breast cancers and potential therapeutic targets.

Top news of the week from Specialty Pharmacy Times.

Older women undergoing chemotherapy for breast cancer have a higher risk of experiencing a decline in their ability to function physically.

The effect of chemotherapy on functional status can be critical for older adults, as declining function can inhibit the ability to live independently and perform daily activities.

Some older women undergoing chemotherapy for breast cancer may be more susceptible to declining physical function and inability to recover function.

The cumulative economic toll that breast cancer treatment has on survivors and their families carries long-term financial implications, according to a recent study in the Journal of Supportive Care and Cancer.

Survivors of breast cancer and their families face long-term cumulative financial implications from treatment and associated costs.

Women who carry the BRCA1 and BRCA2 gene mutations are at an increased risk of breast and ovarian cancer, yet many women are unaware of their mutation status.

A look at last week's top stories in the world of pharmacy.

Globally, lung cancer mortality rates among women are projected to increase by 43% from 2015 to 2030.

Advancements in breast cancer treatment have improved survival rates, but financial hardships related to the cost of these lifesaving therapies can weigh heavily on patients.